Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.
The deal marks GSK's first major transaction under CEO Luke Miels
Jun 09, 2026
05:24 pm
What's the storyBritish pharmaceutical giant GlaxoSmithKline (GSK) has announced its acquisition of US-based biopharmaceutical company Nuvalent for $10.6 billion.
The deal, which marks GSK's first major transaction under CEO Luke Miels, will see the British drugmaker pay $124 per share in cash, a 40% premium to Nuvalent's closing share price on Monday.
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. |…
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
The acquisition is thought to be GSK’s biggest deal in more than a decade.
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and…
